FDA announced new and expanded compounding research projects. The National Academies of Science, Engineering & Medicine will conduct two studies: ● the first will examine the clinical utility of treating patients with compounded bioidentical hormone replacement therapy products, and ● the second study will examine available evidence on multi-ingredient compounded topical pain creams. The agency also expanded two previously announced research collaborations to gather and analyze important information for developing the list of bulk drug substances, or APIs, that may be used in compounding by outsourcing facilities. These institutions will conduct research to help inform the public and the agency’s policies regarding compounded drugs.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
